First Community Trust NA Lowers Stake in Johnson & Johnson (NYSE:JNJ)

First Community Trust NA cut its position in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 3.2% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,369 shares of the company’s stock after selling 175 shares during the quarter. Johnson & Johnson makes up 1.1% of First Community Trust NA’s investment portfolio, making the stock its 22nd largest position. First Community Trust NA’s holdings in Johnson & Johnson were worth $953,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Magnolia Capital Management Ltd. lifted its position in shares of Johnson & Johnson by 0.5% during the first quarter. Magnolia Capital Management Ltd. now owns 11,162 shares of the company’s stock worth $1,978,000 after purchasing an additional 55 shares in the last quarter. Howard Financial Services LTD. raised its holdings in Johnson & Johnson by 2.1% in the first quarter. Howard Financial Services LTD. now owns 2,757 shares of the company’s stock valued at $489,000 after acquiring an additional 57 shares in the last quarter. American Financial Advisors LLC raised its holdings in Johnson & Johnson by 2.1% in the first quarter. American Financial Advisors LLC now owns 2,715 shares of the company’s stock valued at $481,000 after acquiring an additional 57 shares in the last quarter. Taylor & Morgan Wealth Management LLC raised its holdings in Johnson & Johnson by 1.6% in the second quarter. Taylor & Morgan Wealth Management LLC now owns 3,580 shares of the company’s stock valued at $635,000 after acquiring an additional 57 shares in the last quarter. Finally, Kwmg LLC raised its holdings in Johnson & Johnson by 2.6% in the first quarter. Kwmg LLC now owns 2,354 shares of the company’s stock valued at $417,000 after acquiring an additional 59 shares in the last quarter. 68.59% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Performance

JNJ stock opened at $167.60 on Monday. The company has a market capitalization of $440.65 billion, a P/E ratio of 24.40, a PEG ratio of 2.99 and a beta of 0.61. The company has a 50-day simple moving average of $168.96 and a 200 day simple moving average of $174.29. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69. The company has a quick ratio of 1.17, a current ratio of 1.42 and a debt-to-equity ratio of 0.37.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.57 by $0.02. The business had revenue of $24.02 billion during the quarter, compared to the consensus estimate of $23.85 billion. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.14%. The company’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.48 earnings per share. Sell-side analysts predict that Johnson & Johnson will post 10.7 earnings per share for the current fiscal year.

Johnson & Johnson announced that its Board of Directors has authorized a share buyback plan on Wednesday, September 14th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the company to repurchase up to 1.2% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s management believes its shares are undervalued.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd were issued a $1.13 dividend. This represents a $4.52 annualized dividend and a yield of 2.70%. The ex-dividend date of this dividend was Monday, August 22nd. Johnson & Johnson’s payout ratio is currently 65.79%.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several recent analyst reports. SVB Leerink cut their price target on shares of Johnson & Johnson from $200.00 to $194.00 in a report on Wednesday, July 20th. Citigroup lowered their target price on shares of Johnson & Johnson from $205.00 to $201.00 in a research note on Wednesday, July 20th. UBS Group lowered their target price on shares of Johnson & Johnson from $185.00 to $180.00 in a research note on Thursday, July 21st. Morgan Stanley lowered their target price on shares of Johnson & Johnson from $174.00 to $173.00 and set an “equal weight” rating for the company in a research note on Monday, September 12th. Finally, Daiwa Capital Markets initiated coverage on shares of Johnson & Johnson in a research note on Wednesday, June 22nd. They set an “outperform” rating for the company. Four equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $189.78.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.